Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019
Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019
SUMMARY
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Respiratory, Metabolic Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Hidradenitis Suppurativa, Psoriatic Arthritis, Vitiligo, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Hypersensitivity, Kidney Cancer (Renal Cell Cancer), Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Respiratory, Metabolic Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Hidradenitis Suppurativa, Psoriatic Arthritis, Vitiligo, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Hypersensitivity, Kidney Cancer (Renal Cell Cancer), Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
ABBV-712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031407 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06826647 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAKs for Lung Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TYK2 for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-8236 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Portola Pharmaceuticals presents new interim data at the 61st ASH meeting on its oral SYK/JAK inhibitor Cerdulatinib in heavily pre-treated patients with relapsed/refractory follicular lymphoma
Dec 08, 2019: Portola Pharmaceuticals presents new interim data from ongoing phase 2a study of its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated T-Cell Malignancies
Dec 03, 2019: Theravance Biopharma announces dosing of first patient in phase 2 allergen challenge study of TD-8236, an investigational, Lung-selective, inhaled pan-janus kinase (JAK) inhibitor for inflammatory lung diseases
Dec 03, 2019: Dermavant announces first patient dosed in phase 2a clinical trial of topical dual JAK/Syk inhibitor Cerdulatinib for Vitiligo
Oct 30, 2019: Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action
Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract
Sep 27, 2019: Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models
Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases
Jun 19, 2019: Portola presents new interim data on its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated patients with Relapsed/Refractory Follicular Lymphoma
May 21, 2019: Theravance Biopharma reports data from phase 1b study of TD-1473 in oral presentation at Digestive Disease Week (DDW) 2019
May 14, 2019: Theravance Biopharma announces data from phase 1b study of TD-1473 to be featured in oral presentation at Digestive Disease Week (DDW) 2019
Apr 23, 2019: Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int’l Convention in Philadelphia
Mar 12, 2019: Theravance Biopharma announces first patient dosed in phase 2b/3 study of TD-1473 in patients with ulcerative colitis
Dec 06, 2018: Dermavant Sciences to present new data on Cerdulatinib for atopic dermatitis and vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
Dec 03, 2018: Updated interim results from ongoing phase 2a study of Portola Pharmaceuticals' oral Syk/JAK inhibitor Cerdulatinib continues to demonstrate clinical responses in heavily pre-treated T-Cell Malignancies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
ABBV-712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031407 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06826647 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAKs for Lung Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TYK2 for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-8236 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Portola Pharmaceuticals presents new interim data at the 61st ASH meeting on its oral SYK/JAK inhibitor Cerdulatinib in heavily pre-treated patients with relapsed/refractory follicular lymphoma
Dec 08, 2019: Portola Pharmaceuticals presents new interim data from ongoing phase 2a study of its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated T-Cell Malignancies
Dec 03, 2019: Theravance Biopharma announces dosing of first patient in phase 2 allergen challenge study of TD-8236, an investigational, Lung-selective, inhaled pan-janus kinase (JAK) inhibitor for inflammatory lung diseases
Dec 03, 2019: Dermavant announces first patient dosed in phase 2a clinical trial of topical dual JAK/Syk inhibitor Cerdulatinib for Vitiligo
Oct 30, 2019: Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action
Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract
Sep 27, 2019: Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models
Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases
Jun 19, 2019: Portola presents new interim data on its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated patients with Relapsed/Refractory Follicular Lymphoma
May 21, 2019: Theravance Biopharma reports data from phase 1b study of TD-1473 in oral presentation at Digestive Disease Week (DDW) 2019
May 14, 2019: Theravance Biopharma announces data from phase 1b study of TD-1473 to be featured in oral presentation at Digestive Disease Week (DDW) 2019
Apr 23, 2019: Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int’l Convention in Philadelphia
Mar 12, 2019: Theravance Biopharma announces first patient dosed in phase 2b/3 study of TD-1473 in patients with ulcerative colitis
Dec 06, 2018: Dermavant Sciences to present new data on Cerdulatinib for atopic dermatitis and vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
Dec 03, 2018: Updated interim results from ongoing phase 2a study of Portola Pharmaceuticals' oral Syk/JAK inhibitor Cerdulatinib continues to demonstrate clinical responses in heavily pre-treated T-Cell Malignancies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nimbus Therapeutics LLC, H2 2019
Pipeline by Oncostellae SL, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Portola Pharmaceuticals Inc, H2 2019
Pipeline by Sareum Holdings Plc, H2 2019
Pipeline by Simcere Pharmaceutical Group, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nimbus Therapeutics LLC, H2 2019
Pipeline by Oncostellae SL, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Portola Pharmaceuticals Inc, H2 2019
Pipeline by Sareum Holdings Plc, H2 2019
Pipeline by Simcere Pharmaceutical Group, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
